Conference Coverage

ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer

Publish date: December 8, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. de Boer is on the speakers’ bureau for Novartis. Dr. Ingle said he had no financial conflicts to disclose.

Pages

Recommended Reading

BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
MDedge Hematology and Oncology
Breast Cancer Gene Profile Identifies Early vs. Late Recurrences
MDedge Hematology and Oncology
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
MDedge Hematology and Oncology
FDA Drops Restrictions for Thrombocytopenia Treatments
MDedge Hematology and Oncology
IOM Dissects Environmental Risk Factors for Breast Cancer
MDedge Hematology and Oncology
Dual HER2 Blockade Defers Breast Cancer Progression
MDedge Hematology and Oncology
DCIS Assay Predicts Recurrence Risk After Breast Surgery
MDedge Hematology and Oncology
Clodronate Offered Modest Benefit for Breast Cancer Patients
MDedge Hematology and Oncology
Panel Endorses Surveillance for Low-Risk Prostate Cancer
MDedge Hematology and Oncology
Medicare Study Confirms Colonoscopy's Cancer Prevention Power
MDedge Hematology and Oncology